A recent study found that DLBCL patients with tumors harboring P53 alterations had lower responses and survival after CART19 therapies, particularly following a 4-1BB costimulated second-generation CART19 (32). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.